Anheuser-Busch Companies (NYSE: BUD), the manufacturer of popular beer brand Budweiser, Tuesday reported an increase in first-quarter earnings, supported by strong sales in key markets like Brazil and China.
Earnings of the Belgium-based beverages company, excluding special items, climbed to $1.27 per share in the March-quarter from $0.73 per share a year earlier. Unadjusted net profit attributable to stockholders was $3.57 billion or $1.80 per share, up from $1.02 billion or $0.52 per share reported in the first quarter of 2018.
Reported revenues declined 4% year-over-year to $12.6 billion during the three-month period. The top-line was broadly in line with analysts’ forecast. Meanwhile, there was a 5.9% organic revenue growth, reflecting the strong sales performance in key markets including Brazil, China, the US, Europe, Colombia, and Nigeria.
There was a 5.9% organic revenue growth, reflecting the strong sales performance in key markets including Brazil, China, the US, Europe, Colombia, and Nigeria
Looking ahead, the company expects to deliver strong revenue and EBITDA growth in fiscal 2019, supported by improved brand performance and commercial plans. Cost of sales per hl is expected to increase by mid-single digits, with cost management initiatives offsetting the currency and commodity headwinds.
Average gross debt coupon is expected to be between 3.75-4% in fiscal 2019, while the normalized effective tax rate is forecast to be in the range of 25% to 27%. The estimate for net capital expenditure is $4- 4.5 billion. Dividends are expected to grow over time, although growth in the short term is expected to be modest due to deleveraging commitments.
Related: Anheuser-Busch InBev Q4 2018 Earnings Conference Call Transcript
The company’s shares dropped about 1.5% early Tuesday, after closing the previous session lower. The stock has gained 33% since the beginning of the year.
Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
